US Patent

US8470818 — Compounds and methods for kinase modulation, and indications therefor

Method of Use · Assigned to Plexxikon Inc · Expires 2026-08-02 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods for modulating protein kinases, which can be used to treat diseases and conditions associated with aberrant protein kinase activity.

USPTO Abstract

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Drugs covered by this patent

Zelboraf (vemurafenib) · Hoffmann La Roche

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2164`	—	Zelboraf

Patent Metadata

Patent number: US8470818
Jurisdiction: US
Classification: Method of Use
Expires: 2026-08-02
Drug substance claim: No
Drug product claim: No
Assignee: Plexxikon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.